Know-How Protection in Pharmaceutical Companies

Four years have passed since the first proposal of the strategic plan Made in China 2025 (MiC 2025). Although China is toning down the public media coverage and official statements regarding the MiC 2025, the plan is still running. Its goals focus on high-tech areas, including the pharmaceutical industry. The MiC 2025 plan sets ambitious… Continue reading Know-How Protection in Pharmaceutical Companies

Made in China 2025 – Increasing Risks

China’s plan to transform its economy by building its own high-tech capacity and creating national champions holds both opportunities and risks for many Western companies. As Chinese industry moves up the value chain, Chinese companies try to buy or collaborate with high-quality machinery, equipment and services that can support their own transformation with relevant expertise,… Continue reading Made in China 2025 – Increasing Risks

Dangerous Simplification

Referring to the article “Patentes Märchen” (“patent fairy tale”) in the WirtschaftsWoche magazine No. 42 of October 12, 2018: It is common knowledge that complex issues can only be understood through differentiated analysis. This especially applies to the international patent system. To the German industry, it is well-known that China subsidies Chinese patent applications and… Continue reading Dangerous Simplification